NASDAQ:IRD Opus Genetics Q2 2026 Earnings Report $3.73 +0.02 (+0.54%) As of 09:51 AM Eastern ProfileEarnings HistoryForecast Opus Genetics EPS ResultsActual EPSN/AConsensus EPS -$0.15Beat/MissN/AOne Year Ago EPSN/AOpus Genetics Revenue ResultsActual RevenueN/AExpected Revenue$2.63 millionBeat/MissN/AYoY Revenue GrowthN/AOpus Genetics Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time12:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Opus Genetics Earnings HeadlinesOpus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness DisorderAugust 4 at 2:05 PM | finance.yahoo.comOpus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal DiseaseAugust 3 at 7:00 AM | globenewswire.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.August 5 at 1:00 AM | Altimetry (Ad)Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX) and Opus Genetics (IRD)July 31, 2026 | theglobeandmail.comCantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)July 11, 2026 | theglobeandmail.comOpus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 ResultsJuly 9, 2026 | globenewswire.comSee More Opus Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email. Email Address About Opus GeneticsOpus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.View Opus Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Caterpillar’s Record Quarter May Have Reset the Stock’s CeilingGrab Holdings Stock Forms Bottom After Strong Beat-and-Raise QuarterThe AI Chip Stock Making a Quiet Move Toward DominanceThe Real Reason Amazon Hit a $3 Trillion ValuationApple’s AI Strategy Looks Different—Will It Pay Off?Reddit’s U.S. User Decline Raises a Bigger Question After Its Earnings BeatWhy Walmart and Amazon Could Be the Market’s Most Complementary Mega-Caps Upcoming Earnings Airbnb (8/6/2026)Warner Bros. Discovery (8/6/2026)Monster Beverage (8/6/2026)Canadian Natural Resources (8/6/2026)ConocoPhillips (8/6/2026)Cheniere Energy (8/6/2026)Petroleo Brasileiro S.A.- Petrobras (8/6/2026)Targa Resources (8/6/2026)Aflac (8/6/2026)Howmet Aerospace (8/6/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
